

# Schedule of Events

8:15-8:45 AM Breakfast/Registration

8:50-9:00 AM Opening Remarks

9:00-10:20 AM 1<sup>st</sup> Slide Session

**Elizabeth Westgate**

*The Molecular Clock and Circadian Variability in Blood Pressure and Thrombosis*

**Steve Rudnick**

*Differential Effects of Secondary Structure on Antisense Oligonucleotide and Short Interfering RNA Mediated mRNA Cleavage*

**Eric Klein**

*The Role of Cellular Tension in G1-Phase Progression*

**Gene Ciccimaro**

*Probing the Interaction of Focal Adhesion Kinase and c-Src Using Mass Spectrometry*

10:30-11:25 PM 1<sup>st</sup> Poster Session

11:30-12:30 PM Luncheon

12:30-1:30 PM 2<sup>nd</sup> Poster Session

1:40-3:00 PM 2<sup>nd</sup> Slide Session

**Bisen Ding**

*Prophylactic thrombolysis in the pulmonary vasculature by PECAM-directed endothelial surface targeting of a PAI-1 resistant mutant pro-urokinase fusion construct that is activated and released by thrombin*

**Erin Griner**

*Generation of an I130A  $\beta$ 2-chimaerin Knock-in Mouse to Study the Function of  $\beta$ 2-chimaerin in vivo*

**David Kim**

*The Relative Role of DAF and Crry in Protecting Host Cells from Complement Attack*

**Elizabeth Schwarzbach**

*Defining the Mechanisms Contributing To Cognitive Impairment And Seizure Disorders Following Traumatic Brain Injury*

3:00-4:00 PM The John S. O'Brien Memorial Lecture:  
*Creating New Hope: Translating Genomics into Medicine*

**Dr. Peter S. Kim**

President, Merck Research Laboratories

4:00 -4:50 PM Cheese and wine

## The John S. O'Brien Memorial Lecture in Pharmacology



### **“Creating New Hope: Translating Genomics into Medicine”**

Peter S. Kim, Ph.D.  
President,  
Merck Research Laboratories

Peter S. Kim, Ph.D., 48, is a structural biologist known for discovering how proteins cause membranes to fuse, a central feature of all life. He has designed novel compounds that stop membrane fusion by the AIDS virus, thereby preventing it from infecting cells.

Dr. Kim was appointed president of Merck & Co.'s Merck Research Laboratories (MRL) on January 1, 2003, and he is responsible for all of Merck's drug and vaccine discovery and development activities. Previously, Dr. Kim served as MRL's executive vice president of Research and Development from February 1, 2001 to December 31, 2002.

Prior to joining Merck, Dr. Kim was a Professor of Biology at Massachusetts Institute of Technology (MIT). He was also a Member of the Whitehead Institute and an Investigator at the Howard Hughes Medical Institute. Dr. Kim also served as a member of the National Institutes of Health (NIH) Advisory Committee to develop an AIDS vaccine.

Dr. Kim received his undergraduate education at Cornell University, graduating with distinction in chemistry. He received his Ph.D. in biochemistry from Stanford University in 1985. While at Stanford, he was also a Medical Scientist Training Program Fellow.

His work has earned him numerous awards including the National Academy of Sciences Award in Molecular Biology, the Eli Lilly Award in Biological Chemistry, the Hans Neurath Award of the Protein Society, and the Samsung Foundation Ho-Am Prize in Basic Science. Dr. Kim was elected a member of the National Academy of Sciences in 1997 and is also a member of its Institute of Medicine.

Dr. Kim currently is a member of the Board of Directors at Fox Chase Cancer Center and at the Whitehead Institute for Biomedical Research. He is a member of the Oversight Committee, Division on Earth and Life Studies of the National Academies and a member of the Council of the Institute of Medicine.